Introduction {#s1}
============

Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain cancer in adults. Despite improvements in clinical care, a rapid disease progression and insufficient understanding of the etiology of these tumors results in very poor survival prognosis. The standard treatment for GBM patients involves a combination of the DNA damaging agent temozolomide together with radiotherapy ([@bib49]). However, the benefits of current treatment regimes come with severe side effects for patients, as well as drug resistance and inevitable recurrence of the tumor ([@bib57]).

Over recent years, great efforts by individual research groups and consortia have shed light on the key genetic events that lie at the heart of human GBM formation, raising the possibility of a more targeted approach to therapy. This has identified activation of growth factor receptor signaling (for example by amplification or overexpression of the PDGF receptor) and direct or indirect inactivation of the TP53 and retinoblastoma tumor suppressors as core deregulated pathways in human GBM ([@bib9]). Unfortunately, many of these pathways are difficult to target pharmacologically in vivo, and for others, like PDGFR signaling, available inhibitors have so far lacked clinical impact ([@bib58]; [@bib44]). Hence, an important goal of GBM research is to identify novel, more effective therapies to generate better outcomes.

One of the central determinants of tumor progression and the response to therapy is the DNA damage response ([@bib36]). The DNA damage kinase ATM is known primarily as a tumor suppressor, through its role in the response to DNA double-strand breaks ([@bib46]), and systemic loss of ATM has previously been shown to accelerate glioblastoma progression ([@bib47]). This tumor suppressive role is in line with the activation of the DNA damage response in precancerous lesions as a barrier to tumorigenesis ([@bib4]). A recent study has, however, demonstrated loss of ATM signaling to inhibit the growth of TP53-null tumor xenografts, via stabilization of p14^ARF^ ([@bib53]), suggesting that ATM function in cancer is highly context-dependent.

As well as its canonical activation at break sites, ATM signaling also occurs in response to other cellular stresses ([@bib2]), and this mode of ATM signaling requires the ATM INteractor ATMIN ([@bib30]). ATMIN interacts with the ATM kinase in basal conditions and disassociates from ATM in response to ionizing radiation, to allow ATM to interact with the MRN complex at double-strand break sites ([@bib60]). ATMIN also has ATM-independent functions, most notably the transcriptional activation of Dynll1, a motor protein involved with ciliogenesis and crucial for lung development ([@bib28]; [@bib18]). In addition, ATMIN has been shown to counteract oxidative damage in the brain ([@bib31]) and to protect against B cell lymphomagenesis ([@bib35]), but its role in other cancer types has not yet been determined.

A key downstream mediator of the DNA damage response pathway, activated by both the double-strand break and ATMIN-dependent responses, is the tumor suppressor TP53. Precancerous lesions in which the DNA damage response is activated are under selective pressure to lose or mutate *TP53*, and loss of *TP53* is known to cooperate with several genes to accelerate tumorigenesis (as summarized in the IARC database \[[@bib40]\]). Among these cooperating changes is loss of *ATM*, which induces rapid T-cell lymphoma development ([@bib59]). *TP53* is also one of the most commonly mutated genes in human GBM. Consequently, the majority of available mouse models of GBM use deletion of one or both copies of the *Trp53* gene in combination with other mutations ([@bib10]). Overexpression of the Pdgf receptor ligand *Pdgfrb* in adult Nestin-positive neural stem cells, for instance, results in glioma formation, which is accelerated in a *Trp53*-mutant background ([@bib47]).

In this study, we demonstrate that congenital loss of *Trp53* in the mouse brain is sufficient to precipitate spontaneous glioblastoma formation, and that this correlates with upregulation of *Pdgfra*. Further, we show that ATMIN plays a critical role in GBM formation, promoting Pdgfra protein and gene expression in a *Trp53*-deficient background, using an in vivo glioma model as well as neural stem cell and primary tumor cell cultures. Importantly, we find that these results are translatable to therapeutic ATM inhibition in human patient-derived GBM stem cells, and that combining ATM inhibition with PDGFRA inhibition results in synergistic tumor cell killing with minimal effects on untransformed cells.

Results {#s2}
=======

Glioblastomas develop at high frequency in *p53^ΔN^ (Trp53* mutant) mice {#s2-1}
------------------------------------------------------------------------

Loss of *TP53* is one of the earliest occurring events in human GBM initiation ([@bib37]; [@bib56]; [@bib39]; [@bib38]; [@bib26]). This inevitably results in the accumulation of a plethora of secondary hits, which, after a long latency period, leads to tumor formation. To recapitulate this chain of events in mice, we deleted *Trp53* as an initial driver during neural development (using *p53^f/f^; Nestin-Cre (p53^ΔN^*) mice) and monitored brain tumor formation in late adult life. After 8 months, brain tumors arose in *p53^ΔN^* mice with high penetrance ([Figure 1A and B](#fig1){ref-type="fig"}), similar to previous observations using an *hGFAP-Cre* model ([@bib56]). Animals began to show neurological symptoms including reduced movements and tremor at an average age of 263 days. When examined histologically, many *p53^ΔN^* tumors had features consistent with WHO classification criteria for Grade IV GBM ([Figure 1C](#fig1){ref-type="fig"}). Out of 17 animals, 14 (82%) showed diffusely infiltrative astrocytic brain tumors, the majority of which were classified as GBM by independent analysis (57% Grade IV, glioblastoma; 29% Grade III, anaplastic astrocytoma; 14% Grade II, fibrillary astrocytoma), while one displayed an osteosarcoma ([Figure 1B and D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). *p53^ΔN^* GBMs displayed pseudopalisading necrosis (i), microvascular proliferation with endothelial hyperplasia (ii) and occasional endovascular thrombosis (iii), hallmarks of human GBM tumors ([Figure 1E](#fig1){ref-type="fig"} \[i--iii\]). The markers Gfap (iv), Nestin (v), and Olig2 (vi) were expressed in all tumors, while they were negative for the neuronal marker NeuN, supporting the diagnosis of glioma ([Figure 1E](#fig1){ref-type="fig"} (iv--vi) and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Intertumoral and intratumoral heterogeneity, a classic hallmark of high-grade gliomas, was also frequently observed ([Figure 1F](#fig1){ref-type="fig"}). These data indicate that early embryonic loss of *Trp*53 in the brain is sufficient to promote GBM formation. The long latency of these tumors, together with the genome instability and transcriptional changes known to be induced by loss of *Trp*53, indicated that these gliomas almost certainly develop as a result of secondary mutations arising in the *Trp*53-null brain. In line with this notion, mouse SNP array data revealed large chromosomal gains and losses (typical tumorigenic genetic changes) in four out of five analyzed *p53^ΔN^*gliomas, whereas no changes were detected in one wt and three Trp53-deficient non-tumorigenic control NS cells ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). These secondary hits are not congenitally predefined and thus possibly allow a better representation of the genetic diversity of the disease in patients. In addition, the high frequency of brain tumor formation, proportion of high-grade tumors, and consistency of tumor latency on a mixed genetic background make this a valuable GBM model.10.7554/eLife.08711.003Figure 1.Loss of *Trp53* is sufficient to induce GBM with high penetrance.(**A**) Kaplan-Meier curves showing tumor-free survival in *p53^f/f^*; Nestin-Cre (*p53^ΔN^*) and control Nestin-Cre mice. (**B**) Status of mouse cohorts at 450 days, showing tumor incidence. (**C**) H&E-stained *p53^ΔN^* brain tumor sections showing histological features of malignant GBM. Arrowheads indicate (i) a mitotic cell, (ii) neo-vascularization, (iii) rosetta formation, (iv) mitotic catastrophe, (v) a multinucleated giant cell, and (vi) large areas of necrosis. (**D**) Grades of gliomas for *p53^ΔN^* mice. (**E**) Examples of human GBM hallmarks observed in *p53^ΔN^* tumors: pseudopalisading necrosis (i), microvascular proliferation with endothelial hyperplasia (ii), and endovascular thrombosis (iii) (all H&E). Immunohistochemistry shows expression of the glial markers GFAP (iv), NESTIN (v), and OLIG2 (vi) in *p53^ΔN^* tumors. (**F**) *p53^ΔN^* glioblastomas display high inter- and intra-tumoral heterogeneity. H&E images i-ii, iii-iv, and v-vi represent different regions of the same tumors \#1, \#2, and \#3 respectively. GBM, Glioblastoma multiforme.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.003](10.7554/eLife.08711.003)10.7554/eLife.08711.004Figure 1---figure supplement 1.Histological features of lower grade tumors observed in *p53^ΔN^* animals.Hematoxylin and Eosin (H&E) and antibody-stained sections of *p53^ΔN^* brains showing representative examples of low-grade fibrillary astrocytoma (WHO Grade II) and anaplastic astrocytoma (WHO Grade III). Ki67 immunolabeling indicates progressively increased proliferation of atypical glial cells with increased tumor grade**DOI:** [http://dx.doi.org/10.7554/eLife.08711.004](10.7554/eLife.08711.004)10.7554/eLife.08711.005Figure 1---figure supplement 2.Histological features of glioblastomas observed in *p53^ΔN^* animals.H&E and immunohistochemical staining of sections from *p53^ΔN^* control brain tissue (top row) and gliomas (lower row). \'N\' denotes the normal brain region adjacent to the tumor mass.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.005](10.7554/eLife.08711.005)10.7554/eLife.08711.006Figure 1---figure supplement 3.SNP array analysis on primary cells derived from GBM bearing *p53^ΔN^*, non-tumor bearing *p53^ΔN^ , *and wild-type (wt) animals.Chromosomal copy number variations are found in primary tumor cells derived from *p53^ΔN^* gliomas ([@bib49]; [@bib57]; [@bib9]; [@bib58]; [@bib44]) but not in non-tumorous adult *p53^ΔN^* NSCs ([@bib49]; [@bib57]; [@bib9]) or adult wt NSCs. Log R Ratio plots show copy number states for all mouse autosomes for tumor, wt, and *p53^ΔN^* cells. Grey points represent probes in a normal copy number state. Green and light green represents gain and amplification calls, respectively, while red and light red points represent hemi- and homozygous losses, respectively. NSC, Neural stem cell.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.006](10.7554/eLife.08711.006)10.7554/eLife.08711.007Figure 1---figure supplement 4.Table representing CGHcall output for SNP array analysis compressed to comparable regions between arrays in the series.Genomic position and corresponding CGHcall copy number state of samples (0 -- homozygous loss, 1 -- hemizygous loss, 2 -- normal state, 3 -- gain, 4 -- amplification) are included in the table.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.007](10.7554/eLife.08711.007)

Loss of Atmin strongly suppresses GBM formation in the *p53^ΔN^* model {#s2-2}
----------------------------------------------------------------------

As an integral part of the response to genomic stress, activation of the DNA damage response pathway typically represents a barrier to tumorigenesis. Consistent with this, it has previously been shown that loss of the DNA damage kinase Atm accelerates tumorigenesis in a Pdgf-driven glioblastoma model ([@bib47]). In addition, deletion of the Atm cofactor Atmin promotes B cell lymphomagenesis ([@bib35]). Whether loss of Atmin affects tumorigenesis in other cancer types is so far unknown. To investigate the potential role of Atmin in glioma formation, we crossed *Atmin^ΔN^* mice ([@bib31]) with *p53^ΔN^* mice. Strikingly, *Atmin^ΔN^*; *p53^ΔN^* mice showed significantly longer tumor-free survival than *p53^ΔN^*animals (p\<0.0002) ([Figure 2A](#fig2){ref-type="fig"}). The largest proportion of *Atmin^ΔN^*; *p53^ΔN^*mice (43%) did not develop any signs of sickness and were still alive after 450 days; a further 36% succumbed either to non-tumor-related illness or, in one case, a pancreatic tumor ([Figure 2B](#fig2){ref-type="fig"} and [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Only three animals out of a cohort of 14 *Atmin^ΔN^*; *p53^ΔN^*double mutants (21%) initiated glial tumors ([Figure 2B](#fig2){ref-type="fig"}), compared with 82% of *p53^ΔN^*mice over the same period. The three GBMs arising in *Atmin^ΔN^*; *p53^ΔN^*double-mutant mice arose later but were histologically similar to those observed in *p53^ΔN^* mice ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), and did not escape *Atmin* deletion, suggesting that the requirement for Atmin can eventually be overcome, but only in a small proportion of cases. Importantly, central nervous system deletion of *Atmin* alone (*Atmin^ΔN^*) did not affect brain morphology or histology ([@bib31]) and the mice remained tumor free ([Figure 2A](#fig2){ref-type="fig"}). Thus, *Atmin* deletion strongly suppresses GBM formation in *p53^ΔN^* animals.10.7554/eLife.08711.008Figure 2.Loss of *Atmin* rescues GBM formation in *p53^ΔN^* brains.(**A**) Kaplan-Meier curves showing tumor-free survival in *Atmin^ΔN^* and *Atmin^ΔN^; p53^ΔN^* mice. *p53^ΔN^* curve from [Figure 1A](#fig1){ref-type="fig"} (same experiment) is shown for comparison. (**B**) Status of mouse cohorts at 450 days, showing tumor incidence. (**C**) Atmin loss rescues the increased proliferation of *p53^ΔN^* NSCs. (**D**) Mean percentage of BrdU-positive NSCs from the indicated genotypes, assessed by FACS following a 2-hr BrdU pulse. (**E**) Mean number of DAPI-permeable (non-viable) cells after IR or (**F**) hypoxia, showing sensitivity of *Atmin^ΔN^; p53^ΔN^* NSCs to hypoxia but not IR. n.s., not significant; \* p\<0.05, \*\* p\<0.01. (**G**) Scheme of orthotopic NSC transplant experiment (left) and Kaplan-Meier curves indicating survival of NOD/SCID mice orthotopically transplanted with *p53^ΔN^* and *Atmin^ΔN^; p53^ΔN^* NSCs (right). Error bars represent the SEM of three biological repeats, and two biological repeats for (**E**). IR, Ionizing radiation; NSC, Neural stem cell.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.008](10.7554/eLife.08711.008)10.7554/eLife.08711.009Figure 2---figure supplement 1.Histological features of glioblastomas observed in *p53^ΔN^* and *Atmin^ΔN^; p53^ΔN^* animals.H&E and immunohistochemical staining of sections from gliomas derived from *Atmin^ΔN^; p53^ΔN^* brains (top row) showing expression of Nestin and Olig2 in the tumor cells as well as scattered expression of Gfap, similar to Grade IV GBMs from *p53^ΔN^* animals (lower row).**DOI:** [http://dx.doi.org/10.7554/eLife.08711.009](10.7554/eLife.08711.009)10.7554/eLife.08711.010Figure 2---figure supplement 2.Examples of murine neural stem cells in culture.Neural stem cells (NSCs) were isolated according to published protocols and cultured first as neurospheres (left), then maintained in adherent culture (center). They maintain the ability to differentiate, as shown by Map2 staining after 5 days (right).**DOI:** [http://dx.doi.org/10.7554/eLife.08711.010](10.7554/eLife.08711.010)10.7554/eLife.08711.011Figure 2---figure supplement 3.*Atmin^ΔN^* NSCs proliferate at a similar rate as wild-type NSCs.Error bars represent the SEM of two biological repeats. NSC, Neural stem cell.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.011](10.7554/eLife.08711.011)10.7554/eLife.08711.012Figure 2---figure supplement 4.Gross genome stability is unaffected in *Atmin/Trp53* double mutant NSCs.(**A**) Percentages of cells in G1, S and G2/M cell cycle phases, as measured by FACS. (**B**) *Atmin^ΔN^; p53^ΔN^*and *p53^ΔN^* NSCs have similar proportions of cells with \>4n DNA content as wild-type NSCs, as judged by FACS of propidium iodide (PI)-stained cells. Representative images of two biological repeats per genotype are shown for (**A**) and (**B**). (**C**) Metaphase spread analysis of chromosome number from NSCs of the indicated genotypes. At least 15 cells were analyzed for each indicated genotype. NSC, Neural stem cell.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.012](10.7554/eLife.08711.012)10.7554/eLife.08711.013Figure 2---figure supplement 5.Radiation-induced arrest is similarly impaired in *Trp53*-mutant and *Atmin/Trp53* double mutant NSCs.Mean average ratio of BrdU-positive IR-treated NSCs relative to untreated NSCs, showing similar impaired arrest in *Atmin^ΔN^; p53^ΔN^*and *p53^ΔN^* NSCs. Error bars represent the SEM of two biological repeats. IR, Ionizing radiation; NSC, Neural stem cell.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.013](10.7554/eLife.08711.013)10.7554/eLife.08711.014Figure 2---figure supplement 6.Tumors arising from orthotopic injection of NSCs are Nestin and Ki67-positive.Adjacent sections from a representative tumor arising from injected *p53^ΔN^* NSCs stained with Nestin and Ki67. Control, uninjected brain. NSC, Neural stem cell.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.014](10.7554/eLife.08711.014)10.7554/eLife.08711.015Figure 2---figure supplement 7.Asymptomatic *Atmin^ΔN^; p53^ΔN^*-injected animals show persistent GFP-positive cells.Bright field and fluorescent images of asymptomatic mouse brains 155 days after injection with wt or *Atmin^ΔN^; p53^ΔN^* NSCs, showing persistence of injected cells. NSC, Neural stem cell**DOI:** [http://dx.doi.org/10.7554/eLife.08711.015](10.7554/eLife.08711.015)

Atmin loss rescues hyperproliferation and sensitivity to hypoxia in *p53^ΔN^*NSCs {#s2-3}
---------------------------------------------------------------------------------

Loss of Trp53 affects diverse fundamental cellular processes including proliferation, genome stability, cell cycle arrest, and apoptosis ([@bib55]). To understand the involvement of Atmin in the suppression of the *Trp53*-null phenotype, we isolated neural stem cells (NSCs) ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) from *p53^ΔN^*embryos and tested the effect of *Atmin* loss on these processes. *p53^ΔN^*NSCs proliferated more rapidly than wild-type (*wt*) controls. This proliferative advantage, however, was rescued in *Atmin^ΔN^*; *p53^ΔN^* NSCs ([Figure 2C and D](#fig2){ref-type="fig"}), indicating that Atmin is required for the hyperproliferation of Trp53-deficient NSCs. Loss of Atmin alone did not alter proliferation of NSCs ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). FACS profiling of *p53^ΔN^* and *Atmin^ΔN^*; *p53^ΔN^* NSCs revealed a decrease in the proportion of *Atmin^ΔN^*; *p53^ΔN^* cells in S phase compared with *p53^ΔN^* NSCs, in agreement with the reduced proliferation rate, but no change in cells with a \>4n DNA content, and metaphase spreads at passage 10 revealed no obvious difference in ploidy ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). We analyzed cell cycle arrest and cell death in response to ionizing radiation (IR) by quantifying the percentage of BrdU-incorporating and DAPI-permeable NSCs respectively. As expected, *p53^ΔN^* NSCs arrested less efficiently than *wt* NSCs and cell death was reduced; but cell cycle arrest and cell death were not rescued in *Atmin^ΔN^*; *p53^ΔN^* NSCs ([Figure 2E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}). In addition to IR-induced cell death, *p53^ΔN^* NSCs were more resilient to hypoxia-induced death, consistent with previous studies ([@bib33]; [@bib21]). *Atmin* deletion in these cells re-sensitized them to hypoxia, to similar levels as *wt* NSCs ([Figure 2F](#fig2){ref-type="fig"}). Thus, loss of Atmin is able to rescue some of the phenotypes of Trp53 loss, such as hyperproliferation and hypoxia induced death, but not others, such as IR-induced cell cycle arrest and cell death.

Loss of Atmin impairs the tumorigenicity of neural stem cells in orthotopic transplants {#s2-4}
---------------------------------------------------------------------------------------

As increased proliferation and hypoxia resistance are attributes commonly found in tumor initiating cells of solid tumors, including glioma ([@bib21]; [@bib17]), we evaluated the tumorigenic potential of *p53^ΔN^* and *Atmin^ΔN^*; *p53^ΔN^* NSCs in vivo. We performed intracranial injections of NSCs isolated from *wt*, *p53^ΔN^*, and *Atmin^ΔN^*; *p53^ΔN^*embryos ([Figure 2G](#fig2){ref-type="fig"}). Five out of five animals injected with *p53*^ΔN^ NSCs died within 93 days post-injection, while four out of five wt and three out of four *p53^ΔN^*; *Atmin^ΔN^*NSC-injected animals were still alive even at 155 days, the endpoint of the experiment ([Figure 2G](#fig2){ref-type="fig"}). Histologically, injected cells appeared as atypical glial cells expressing Nestin and Ki67, diffusely infiltrating the host brain ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}), similar to previous observations with human GBM xenografts ([@bib48]). Fluorescent imaging of asymptomatic mice at the experimental endpoint readily detected injected *Atmin^ΔN^*; *p53^ΔN^* and *wt* NSCs ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}), suggesting that these cells survived in the host brain, but did not induce lethality. Thus, genetic inactivation of *Atmin* greatly impairs the tumorigenic potential of *p53^ΔN^*cells.

Atmin loss normalizes expression of the proto- oncogene *Pdgfra* in *p53^ΔN^* NSCs {#s2-5}
----------------------------------------------------------------------------------

To understand the molecular basis of the observed attenuation of tumorigenic potential, we performed gene expression profiling on *wt*, *p53^ΔN^*, and *Atmin^ΔN^*; *p53^ΔN^*embryonic NSCs. Compared with *wt* NSCs, 145 genes were downregulated more than 1.5-fold in *p53^ΔN^*, whereas 77 were overexpressed ([Figure 3A](#fig3){ref-type="fig"}). Many of the canonical Trp53 target genes, such as *Bax, Puma*, and *Cdkn1a*, were downregulated to a similar extent in *Atmin^ΔN^; p53^ΔN^* compared with *p53^ΔN^*NSCs. However, 27% of genes deregulated in *p53^ΔN^*NSCs returned to *wt* expression levels when Atmin was also deleted (36/145 of the decreased, and 24/77 of the increased genes; examples in [Figure 3B](#fig3){ref-type="fig"}). When this subset of genes 'rescued' in double mutant NSCs was queried against the Cancer Genome Atlas (TCGA) database, in several cases abnormal levels of these transcripts were found to be associated with human GBM ([@bib9]; [@bib50]). Particularly notable among this list was the platelet-derived growth factor receptor alpha (Pdgfra) ([Figure 3C](#fig3){ref-type="fig"}). Elevated levels of *PDGFRA* have been observed in human gliomas of various malignancy grades ([@bib14]), and increased PDGFR signaling has been shown to induce glioma-like growths in vivo ([@bib25]). Increased PDGFRA levels are also a characteristic hallmark of the proneural GBM subtype as classified in ([@bib8]; [@bib54]). Interestingly, we found that *p53^ΔN^*NSCs were associated most closely with the proneural subtype when comparing the microarray expression profile from the murine NSCs to that of publically available human GBM samples from TCGA ([@bib54]) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), which is in agreement with elevated *Pdgfra* mRNA as well as protein levels ([Figure 3D](#fig3){ref-type="fig"}). This increased protein expression was also apparent in high-grade GBMs from endstage *p53^ΔN^*animals ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Other growth factor receptors, like Egfr, and proteins commonly deregulated in glioma including Rb, Pten, Cyclin D2, Junc, and Cdk4 ([@bib56]) remained unaltered in *p53^ΔN^*cells and tumors ([Figure 3---figure supplements 2](#fig3s2){ref-type="fig"} and [3](#fig3s3){ref-type="fig"}), as did the closely related Pdgf receptor *Pdgfrb* and the receptor ligands *Pdgfa* and *Pdgfb* ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}).10.7554/eLife.08711.016Figure 3.Atmin regulates *Pdgfra* expression in a mutant *Trp53* background.(**A**) Heatmap showing genes deregulated more than 1.5-fold in *Trp53* null NSCs and their corresponding expression in *Atmin^ΔN^; p53^ΔN^* double null NSCs. (**B**, **C**) qRT-PCR validation of GBM implicated genes that show deregulated expression in *p53^ΔN^* but not *Atmin^ΔN^; p53^ΔN^* NSCs. (**D**) Elevated Pdgfra protein expression in *p53^ΔN^* but not *Atmin^ΔN^; p53^ΔN^* NSCs. Corresponding p-Akt and total Akt levels were probed to analyze pathway activation. Actin was used as loading control. (**E**) Tumor section from a GBM arising from a *p53^ΔN^* animal showing elevated Pdgfra expression. \'N\' denotes the normal brain region adjacent to the tumor mass. Dotted lines indicate tumor border. (**F**) Myc-Atmin overexpression increases expression of *Pdgfra* mRNA in *Atmin^ΔN^; p53^ΔN^* but not wt cells. (**G**) Myc-Atmin overexpression increases Pdgfra protein levels in *Atmin^ΔN^; p53^ΔN^* NSCs. Tubulin was used as loading control. (**H**) *Atmin* silencing using two independent shRNA constructs reduces *Pdgfra* expression, assessed by qRT-PCR. (**I**) Stable *Pdgfra* silencing using two independent shRNA constructs reduces primary tumor cell proliferation, measured using IncuCyte timelapse microscopy. Error bars represent the SEM of at least three biological repeats and two biological repeats in (**I**).\* p\<0.05, \*\* p\<0.01, \*\*\* p\<0.001. NSC, Neural stem cell**DOI:** [http://dx.doi.org/10.7554/eLife.08711.016](10.7554/eLife.08711.016)10.7554/eLife.08711.017Figure 3---figure supplement 1.The transcriptional profile of *p53^ΔN^* NSCs is most closely related to the human proneural GBM subtype, relative to expected distances.Relative to expected distance away from the centroids, *p53^ΔN^*is closest to the proneural category (p=0.036, simulation test) and the *p53^ΔN^*:proneural pairing is the only one that is significant -- the grey shading represents the lower 5% tail of the simulated distances. NSC, Neural stem cell**DOI:** [http://dx.doi.org/10.7554/eLife.08711.017](10.7554/eLife.08711.017)10.7554/eLife.08711.018Figure 3---figure supplement 2.Pdgfra expression is elevated in *p53^ΔN^*tumors, but Egfr is not.Immunohistochemistry of GBM sections showing elevated Pdgfra, but not Egfr, expression in a *p53^ΔN^* tumor. Esophagus section is shown as positive control for Egfr staining. GBM, Glioblastoma multiforme**DOI:** [http://dx.doi.org/10.7554/eLife.08711.018](10.7554/eLife.08711.018)10.7554/eLife.08711.019Figure 3---figure supplement 3.Some markers frequently altered in GBM are unaltered in *p53^ΔN^* NSCs.Western blots of NSCs of the indicated genotypes showing levels of proteins commonly altered in glioma but unaffected by Atmin/Atm deletion. GBM, Glioblastoma multiforme; NSC, Neural stem cell**DOI:** [http://dx.doi.org/10.7554/eLife.08711.019](10.7554/eLife.08711.019)10.7554/eLife.08711.020Figure 3---figure supplement 4.Pdgf ligand expression is not significantly altered in *p53^ΔN^* NSCs.q-PCR showing similar expression levels of the Pdgfr ligands *Pdgfa* and *Pdgfb* in *p53^ΔN^* and *Atmin^ΔN^; p53^ΔN^* cells. *Pdgfrb* was not detected. Error bars represent the SEM of at least three biological repeats. NSC, Neural stem cell.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.020](10.7554/eLife.08711.020)10.7554/eLife.08711.021Figure 3---figure supplement 5.Two independent shRNAs cause *Pdgfra* knockdown.(**A**) Isolation and culture of *p53^ΔN^* primary tumor cells from affected mice. (**B--C**) Western blot (**B**) and qPCR (**C**) showing knockdown of *Pdgfra* using two independent shRNA constructs. Error bars represent the SEM of at least two biological repeats. \*\*\* p\<0.001**DOI:** [http://dx.doi.org/10.7554/eLife.08711.021](10.7554/eLife.08711.021)10.7554/eLife.08711.022Figure 3---figure supplement 6.miR34a expression is reduced in *p53^ΔN^* NSCs.Error bars represent the SEM of at least three biological repeats. \*\*\* p\<0.001**DOI:** [http://dx.doi.org/10.7554/eLife.08711.022](10.7554/eLife.08711.022)

Importantly, deletion of *Atmin* together with *Trp53* completely rescued the elevated *Pdgfra* expression, reducing it to wild-type levels ([Figure 3C and D](#fig3){ref-type="fig"}). Overexpression of tagged Atmin in double mutant NSCs restored elevated Pdgfra expression at both the mRNA and protein levels ([Figure 3F and G](#fig3){ref-type="fig"}), while acute silencing of *Atmin* in *p53^ΔN^*NSCs, using two independent shRNA constructs, reduced *Pdgfra* levels ([Figure 3H](#fig3){ref-type="fig"}), implying that sustained *Pdgfra* upregulation in *p53^ΔN^*NSCs constantly requires Atmin function to maintain increased *Pdgfra* expression. Thus, interference with Atmin function is sufficient to reduce *Pdgfra* overexpression in *Trp53*-deficient cells.

To assess whether Trp53 null tumors require sustained *Pdgfra* overexpression, we isolated primary tumor cells from GBM-bearing *p53^ΔN^*mice and induced stable knockdown of *Pdgfra* using shRNA ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). This resulted in a significant decrease in the proliferation rate of these primary tumor cells ([Figure 3I](#fig3){ref-type="fig"}), emphasizing the importance of Atmin function in supporting elevated *Pdgfra* expression in *p53^ΔN^*gliomas.

Pdgfra overexpression is reversible with pharmacological Atm inhibition {#s2-6}
-----------------------------------------------------------------------

Atmin has two known functions: an Atm-dependent function, in which Atmin interacts with Atm and is required for Atm signaling in several stress contexts, and an Atm-independent function, in which Atmin is required for transcription of the dynein light chain Dynll1. To determine whether acute silencing of *Atmin* in tumor cells might reduce *Pdgfra* expression by disrupting Atm signaling, we tested the effects of pharmacological Atm inhibition in *p53^ΔN^*primary tumor cells. Treatment with an Atm inhibitor (ATMi) significantly reduced Pdgfra transcript and protein levels ([Figure 4A and B](#fig4){ref-type="fig"}) and efficiently reduced proliferation of *p53^∆N^*primary tumor cells ([Figure 4C](#fig4){ref-type="fig"}), similar to our observations after *Pdgfra* silencing. ATMi treatment also reduced *Pdgfra* expression in *p53^ΔN^*NSCs ([Figure 4D](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Consistent with these results, *Atm*^-/-^; *p53^ΔN^*double-mutant NSCs had dramatically lower *Pdgfra* expression levels than *p53^ΔN^*NSCs, comparable to *Atmin^ΔN^*; *p53^ΔN^*and *wt* NSCs ([Figure 4E and F](#fig4){ref-type="fig"}). Furthermore, in vitro proliferation assays showed that genetic loss of *Atm* reduced the proliferation of *p53^ΔN^*NSCs to *wt* levels ([Figure 4G](#fig4){ref-type="fig"}). Importantly, the reduction in cell proliferation in vitro correlated with reduced tumorigenic potential of the NSCs when orthotopically injected into the brains of NOD/SCID mice. Mice injected with *Atm*^-/-^; *p53^ΔN^*NSCs survived up to 50% longer than those receiving *p53^ΔN^*NSCs ([Figure 4H](#fig4){ref-type="fig"}). However, *Atmin* deletion ([Figure 2G](#fig2){ref-type="fig"}) was more effective than deletion of *Atm* ([Figure 4H](#fig4){ref-type="fig"}). Atmin can also act as a transcription factor ([@bib28]; [@bib29]; [@bib18]), and it is conceivable that this Atm-independent function of Atmin contributes to the suppression on GBM. The similar effect of *Atmin* deletion and Atm inhibition on *Pdgfra* expression and proliferation of NSCs and primary tumor cells supports the hypothesis that Atmin functions in these processes via its modulation of Atm signaling. Given the extensively characterized role of PDGFRA in cell proliferation and in particular in glioma, it is reasonable to propose that the reduction in *Pdgfra* expression upon *Atm* loss contributes to the reduced tumorigenic potential observed.10.7554/eLife.08711.023Figure 4.Atm inhibition reduces *Pdgfra* expression and reduces tumorigenic potential in murine *p53^ΔN^* primary tumor cells and NSCs.(**A--B**) Atm inhibitor (ATMi) treatment reduces Pdgfra protein levels (**A**) and *Pdgfra* expression (**B**) in *p53^ΔN^* primary tumor cells. (**C**) ATMi treatment reduces in vitro proliferation of *p53^ΔN^* primary tumor cells. Error bars represent the SEM of two biological repeats. (**D**) ATMi reduces *Pdgfra* expression in *p53^ΔN^* NSCs, assayed by qPCR. (**E--F**) *Pdgfra* expression (**E**) and Pdgfra protein levels (**F**) are reduced in *Atm*^-/-^; *p53^ΔN^* and *Atmin^ΔN^; p53^ΔN^* compared with *p53^ΔN^* NSCs. cDNA is normalized to *Actin* levels. Error bars represent the SEM of at least three biological repeats. s.e. and l.e. denote short and long exposures of the same blot, respectively. (**G**) Genetic loss of *Atm* reduces in vitro proliferation of *p53^ΔN^* NSCs. Error bars represent the SEM of two biological repeats. (**H**) Kaplan-Meier curves indicating increased survival of NOD/SCID mice orthotopically transplanted with *Atm^-/-^; p53^ΔN^* NSCs compared with *p53^ΔN^* NSCs. n.s., not significant; \* p\<0.05, \*\* p\<0.01, \*\*\* p\<0.001. NSC, Neural stem cell.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.023](10.7554/eLife.08711.023)10.7554/eLife.08711.024Figure 4---figure supplement 1.ATM inhibitor (ATMi) treatment reduces Pdgfra protein levels in *p53^ΔN^* NSCs. NSCs, Neural stem cells.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.024](10.7554/eLife.08711.024)

Since Atm is best known as a DNA damage signaling kinase, we examined whether the effect of Atm on *Pdgfra* expression and tumorigenicity was related to altered DNA damage signaling in *p53**^Δ^**^N^*glioma cells. Neither *p53**^Δ^**^N^*nor *Atmin**^Δ^**^N^*; *p53**^Δ^**^N^*NSCs showed increased γh2ax or 53bp1 foci in basal conditions ([Figure 5A and B](#fig5){ref-type="fig"}), suggesting that the different proliferation rates are not caused by changes in endogenous DNA damage. *Pdgfra* expression was not affected by IR or hydroxyurea (HU), two well-described inducers of ATM signaling, either in wt or in *p53**^Δ^**^N^*NSCs ([Figure 5C](#fig5){ref-type="fig"}) and no increased Atm substrate phosphorylation could be detected in untreated *p53**^Δ^**^N ^*NSCs ([Figure 5D](#fig5){ref-type="fig"}), suggesting that *Pdgfra* upregulation is not a consequence of stimulation of DNA damage signaling. Atm substrate phosphorylation was also comparable in IR- and HU-treated *wt, p53**^Δ^**^N^*and *Atmin**^Δ^**^N^*; *p53**^Δ^**^N^*NSCs ([Figure 5D](#fig5){ref-type="fig"}), suggesting that the response to DNA damage stimuli is comparable in these cells. This suggests that while Atm is required for the increased *Pdgfra* expression in *p53**^Δ^**^N ^*cells, this does not involve alterations in IR or HU-induced Atm signaling, but at this point does not exclude the possibility that increased ROS (reactive oxygen species) levels in *p53^∆N^* GBM cells might contribute to Atm pathway activation and subsequent *Pdgfra* induction and GBM development.10.7554/eLife.08711.025Figure 5.Atm signaling in response to DNA damaging agents is remarkably unaffected in *p53^ΔN^* and *Atmin^ΔN^; p53^ΔN^* cells and DNA damaging treatments do not affect *Pdgfra* expression.(**A**) *p53^ΔN^* and *Atmin^ΔN^; p53^ΔN^* NSCs do not show elevated γh2ax and 53bp1 foci in untreated conditions, suggesting low endogenous damage. Cells treated with 5Gy IR (wt +IR) are shown as a positive control. (**B**) Quantification of γh2ax and 53bp1 foci in (**A**). Error bars indicate 95% confidence intervals. (**C**) qPCR of *Pdgfra* in wt and *p53^ΔN^* NSCs in untreated conditions and after DNA damage-inducing stimuli. cDNA is normalized to *Actin* levels. Error bars represent SEM of three biological repeats. (**D**) Western blots depicting Atm substrate phosphorylation after the indicated stimuli in NSCs of different genotypes.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.025](10.7554/eLife.08711.025)

Primary human glioma neural stem cells are sensitive to ATM inhibition and combinatorial treatment with PDGFR inhibitors {#s2-7}
------------------------------------------------------------------------------------------------------------------------

To investigate the relevance of ATM signaling for *PDGFRA* upregulation in human GBM, we took advantage of patient derived human GBM neural stem cells (GNSCs) ([@bib48]) that have documented *TP53* mutations (lines G26, G166, and G179, [Figure 6A](#fig6){ref-type="fig"}). We confirmed that cell extracts from each of these human tumors were unable to activate a luciferase construct containing multiple TP53-binding elements ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). *PDGFRA* expression was significantly increased in two out of three human GNSC lines compared with untransformed human neural stem cells (cb660; ([@bib14]; [@bib42]) ([Figure 6B](#fig6){ref-type="fig"}). To assess whether this observation is representative of the wider human GBM spectrum, we analyzed the gene expression patterns in the \'Glioblastoma Multiforme (TCGA, provisional)\' dataset from The Cancer Genome Atlas. We analyzed 153 RNA-seq and 500 microarray datasets for 518 glioblastoma samples and completed these with the clinical subgroup information from ([@bib8]). The gene expression datasets contained z-scores representing the differences in expression levels of *PDGFRA* between cancer and control samples ([Figure 6---figure supplements 2](#fig6s2){ref-type="fig"} and [3](#fig6s3){ref-type="fig"}). The RNA-seq and microarray data were handled separately; for each, we observed higher average *PDGFRA* expression in *TP53*-mutant glioblastoma samples compared with *TP53* wild-type samples ([Figure 6C,D](#fig6){ref-type="fig"}). We also observed higher *PDGFRA* expression levels in the Proneural and GCiMP GBM subtypes when compared to the Classical, Neural, and Mesenchymal ([Figure 6E](#fig6){ref-type="fig"} and [Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}).10.7554/eLife.08711.026Figure 6.ATM inhibitor treatment reduces elevated PDGFRA expression and decreases proliferation in human GBM tumor cells.(**A**) Mutational status of *TP53*, *PTEN*, *IDH1*, and *EGFR* in the indicated glioma neural stem stell (GNSC) lines. n.e., not expressed. wt, wild type. (**B**) Western blot depicting PDGFRA, TP53, PTEN, and ACTIN expression in three GNSC lines (G26, G166, and G179) and cb660 control cells. (**C**,**D**) Box plots showing *PDGFRA* expression in TP53-wt and TP53-mutant TCGA human glioblastoma datasets, measured by microarray (n=153). (**C**) or RNA-Seq (n=500). (**D**) Data from 518 patient samples in total with an overlap of 135 patients. (**E**) Box plots showing *PDGFRA* expression z-scores in TCGA human glioblastoma subtypes, measured by RNA-Seq (n=150). p-Values in (**C--E**) calculated using Wilcoxon's test. (**F**) qRT-PCR showing decreased *PDGFRA* expression in TP53-mutant GNSC lines after ATM inhibitor (ATMi) treatment. cDNA is normalized to GAPDH levels. Error bars represent the STDEV of two biological repeats. (**G**) Western blot showing knockdown of PDGFRA using a doxycycline (Dox)-inducible shRNA construct. (**H**) PDGFRA knockdown using doxycycline (Dox)-inducible shRNA reduces proliferation of TP53-mutant G179 GNSCs. Cell confluence measured by IncuCyte timelapse microscopy. Error bars represent the SEM of three biological repeats. \* p\<0.05, \*\*\* p\<0.001, n.s., not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.026](10.7554/eLife.08711.026)10.7554/eLife.08711.027Figure 6---figure supplement 1.Luciferase reporter assay for TP53 activity using the p53-550RE construct in human GNSC (G26, G166, G179) and control NSC (cb660) lines. NSC, Neural stem cell.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.027](10.7554/eLife.08711.027)10.7554/eLife.08711.028Figure 6---figure supplement 2.Correlation of *PDGFRA* expression levels in TCGA glioblastoma samples represented in both microarray and RNASeq datasets.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.028](10.7554/eLife.08711.028)10.7554/eLife.08711.029Figure 6---figure supplement 3.Comparison of the distribution of *PDGFRA* expression levels in human glioblastoma samples measured by RNASeq and by microarray.Data from TCGA.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.029](10.7554/eLife.08711.029)10.7554/eLife.08711.030Figure 6---figure supplement 4.Box plots showing *PDGFRA* expression z-scores in TCGA human glioblastoma subtypes measured by microarray (n=487).p-Value is calculated using Wilcoxon's test, combining GCiMP and Proneural versus Neural, Classical, and Mesenchymal.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.030](10.7554/eLife.08711.030)10.7554/eLife.08711.031Figure 6---figure supplement 5.Control for [Figure 6G and H](#fig6){ref-type="fig"} showing efficient knockdown of *PDGFRA* after doxycycline administration.q-PCR showing knockdown of *PDGFRA* in GNSCs using a doxycycline (Dox)-inducible shRNA construct.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.031](10.7554/eLife.08711.031)

In line with the data from our mouse model, treatment with an ATMi strongly reduced *PDGFRA* expression in GNSCs, whereas no significant effect on *PDGFRA* expression was detected in cb660 controls ([Figure 6F](#fig6){ref-type="fig"}). To determine whether a reduction in *PDGFRA* levels would be sufficient to inhibit the proliferation of primary GNSCs from human tumors, G179 cells were infected with doxycycline (dox)-inducible shRNA constructs targeting *PDGFRA* ([Figure 6G](#fig6){ref-type="fig"} and [Figure 6---figure supplement 5](#fig6s5){ref-type="fig"}), and their proliferation was monitored over a period of 10 days. In agreement with our results in the mouse, depletion of *PDGFRA* led to a significant decrease in the proliferation rate of human GNSCs ([Figure 6H](#fig6){ref-type="fig"}). Thus, both murine and human TP53-mutant glioma cells are sensitive to loss of PDGFRA.

To analyze the physiological effects of ATM inhibition on GNSCs, proliferation was monitored over a period of 7 days. Similar to our observations in murine NSCs, ATMi treatment reduced the proliferation rate of human TP53 mutant GNSCs, but not cb660 control cells ([Figure 7A](#fig7){ref-type="fig"}). PDGFR inhibitors (PDGFRi) have previously been shown in vitro and in vivo to reduce tumor growth in a glioma model ([@bib32]). These advances, however, have so far failed to transition into clinical practice ([@bib58]; [@bib44]). We reasoned that ATMi-mediated reduction in PDGFRA protein levels could potentiate the effects of PDGFR inhibition. Consistent with this, we observed that co-treatment of GNSCs, but not untransformed NSCs (e.g. cb660), with relevant ATM and PDGFR inhibitor concentrations further reduced cell proliferation ([Figure 7A](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). More detailed analysis revealed that this treatment combination induced substantial cell death, while untransformed NSCs remained largely unaffected ([Figure 7B,C](#fig7){ref-type="fig"}). The proportion of apoptotic GNSCs receiving the combination treatment was quantifiable by microscopic detection of a caspase-cleaved fluorescent substrate after up to four days of drug treatment; thereafter, dead cells detached from the plate, precluding accurate quantification. Essentially, all GNSCs were eventually killed by the combination of ATM and PDGFR inhibitors, as judged by cell detachment. In contrast, PDGFRi treatment by itself had little effect on cell death and proliferation ([Figure 7 A--C](#fig7){ref-type="fig"}). Seeding GNSCs at higher confluence gave similar results ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}), as did a second, independent PDGFRi in combination with the ATMi ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}), indicating that cell death was not an indirect consequence of slower proliferation induced by the ATMi or a side effect of a particular drug. Hence, ATM is required for *PDGFRA* overexpression in both murine and human GBM cells, and combined inhibition of ATM and PDGFR induces lethality in TP53-mutant glioma cells, promising new opportunities for future GBM treatment.10.7554/eLife.08711.032Figure 7.Combinatorial treatment with both ATM and PDGFR inhibitors induces apoptosis of human glioma stem cells.(**A**) Growth curves showing the proliferation of wild-type control human neural stem cells (cb660) and two independent cell lines isolated from TP53-deficient human gliomas (G166 & G179) over 7 days in the presence of vehicle control (DMSO), ATM inhibitor (ATMi), PDGFR inhibitor (PDGFRi), or both inhibitors. Error bars depict STDEV from two biological repeats. (**B**) Representative bright-field/fluorescent images of the same cell types treated as above after 4 days. Cells undergoing apoptosis are labeled by emitting GFP. (**C**) Quantification of apoptotic cells after the treatments indicated above, represented as % apoptotic cells from total live cells. Error bars depict STDEV from three biological repeats. After four days, it became impossible to quantify apoptotic GNSCs receiving the combination treatment, since they detached completely from the culture plate. These percentages thus represent an underestimate of the total extent of G166 and G179 cell death with ATMi + PDGFRi.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.032](10.7554/eLife.08711.032)10.7554/eLife.08711.033Figure 7---figure supplement 1.ATM and PDGFR inhibitors were used at minimally required concentration to achieve pathway inhibition.(**A**) G179 cells were treated with DMSO or 400 nM, 2 μM or 10 μM of ATMi for 16 hrs, then subjected to 5Gy of ionizing irradiation, harvested 30 min later and analyzed by Western blotting. Pre-treatment of cells with the ATMi at 10 μM clearly prevented IR-induced ATM auto-phosphorylation at Serine 1981 and phosphorylation of its downstream substrates: KAP1 and CHK2, at Serine 824 and Threonine 68, respectively. (**B**) G179 cells were treated with DMSO, 200 nM or 1 μM of PDGFRA inhibitor III for 2 hrs, harvested and analyzed by Western blotting. 1 μM inhibitor prevented the phosphorylation of AKT (downstream substrate of PDGFRA) at Serine 473. (**C**) P-PDGFRA levels were below detection, therefore total PDGFRA was immunoprecipitated from cell lysates prior to Western blotting. Treatment of cells with the PDGFRA inhibitor III at 1 μM clearly reduced phosphorylation of PDGFRA at Tyrosine 754.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.033](10.7554/eLife.08711.033)10.7554/eLife.08711.034Figure 7---figure supplement 2.Bright-field images of timelapse microscopy using cells seeded at high confluency.Representative bright-field images of cb660, G166, and G179 GNSC lines seeded at high confluency and treated over 7 days with vehicle control (DMSO), ATM inhibitor (ATMi), PDGFR inhibitors III or V, or both ATM and PDGFR inhibitors. Values indicate% confluence at the indicated point in the time course as measured using IncuCyte software.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.034](10.7554/eLife.08711.034)10.7554/eLife.08711.035Figure 7---figure supplement 3.Apoptosis quantification of a second PDGFR inhibitor.(**A**) Representative bright-field/fluorescent images of the same cell types treated over 4 days with vehicle control (DMSO), PDGFR inhibitor V (PDGFRi V), or ATM inhibitor in combination with PDGFR inhibitor V (ATMi + PDGFRi V). Cells undergoing apoptosis are labelled by emitting GFP. (**B**) Quantification of apoptotic cells four days after the treatments indicated above, represented as % apoptotic cells from total live cells. After four days, it became impossible to quantify apoptotic GNSCs receiving the combination treatment, since they detached completely from the culture plate. These percentages thus represent a large underestimate of the extent of G166 and G179 cell death with ATMi + PDGFRi V.**DOI:** [http://dx.doi.org/10.7554/eLife.08711.035](10.7554/eLife.08711.035)

Our data indicate that disruption of Atm/Atmin function not only inhibits GBM initiation in Trp53-deficient animals, but also reduces the tumorigenic potential of established human glioma cells, suggesting that ATM inhibitors might be valuable tools in GBM therapy.

Discussion {#s3}
==========

An important goal of personalized cancer medicine is to identify vulnerabilities of specific tumor genotypes. Since TP53 signaling is the most common genetically altered pathway in human gliomas ([@bib9]), it is desirable for future cancer therapies to identify new molecular targets that affect TP53-deficient cells. Here, we have shown that genetic loss of *Atmin* or *Atm* reduces GBM formation initiated by deletion of *Trp53*. This finding indicates that Atm/Atmin is crucial for Trp53-deficient GBM development, and suggests the use of ATM inhibitors, which have already been developed, for GBM therapy ([@bib5]; [@bib20]; [@bib19]; [@bib6]).

Although other groups have previously observed that loss of *Trp53* is sufficient to provoke GBM formation ([@bib56]; [@bib61]), the potential advantages of this model system have largely been overlooked. Even on a mixed genetic background, mice harboring a Nestin-driven Trp53 deletion show strong consistency in tumor latency, high penetrance of brain tumors and high-grade GBM formation. Such a model, incorporating the stochastic evolution and genetic heterogeneity of human glioblastoma patients, complements existing genetically defined mouse models that show an accelerated disease course ([@bib10]).

Atm is a rare example of a protein required for formation of a *Trp53*-deficient tumor that is amenable to pharmacological inhibition, with potential direct therapeutic implications. This pro-tumorigenic function for Atmin and Atm signaling in brain cancer is unexpected, as systemic Atm deletion has previously been found to accelerate Pdgf ligand-induced gliomagenesis ([@bib47]). However, the previous study was carried out in Trp53 wild-type animals. It was recently shown that TP53 status is crucial in determining the cellular response to ATM inhibition in human glioma cell lines ([@bib7]), so this difference might explain the apparently opposite function of Atm in our model. TCGA data indicates that ATM mutation/deletion is rare in TP53-mutant GBM, supporting the hypothesis that ATM loss is not a tumor driver and may even inhibit tumorigenesis in this context. Because the pleiotropic effects of ATM signaling are highly context dependent, factors other than TP53 status must also influence the outcome in vivo. For example, loss of Atm cooperates with Trp53 deficiency and accelerates the progression of T-cell lymphoma ([@bib59]). Thus, the relationship between TP53 and ATM signaling in tumorigenesis may be tissue specific, ranging from cooperation to antagonism.

Adding to this context dependency, ATM's function in the DNA damage response inhibits tumorigenesis in precancerous lesions but can also promote resistance to DNA damaging therapies in established tumors. Indeed, recently published work has shown that ATM inhibition preferentially radiosensitizes TP53 mutant GBM cell lines ([@bib7]). Our data reveal an additional pro-tumorigenic effect of Atm, which acts in the absence of ionizing radiation and involves non-canonical, Atmin-dependent signaling. It is possible that the effect of Atm inhibition in our model would also be enhanced by ionizing radiation, since the radiosensitizing effect would be predicted to be largely independent of Atmin ([@bib30]). Thus, combination treatment with ATM and PDGFR inhibitors together with radiotherapy may represent a therapeutic opportunity for GBM.

Our results indicate that the requirement for the Atm/Atmin pathway in *p53^∆N^* GBM lies in the initiation of a program of altered gene expression ([Figure 3A](#fig3){ref-type="fig"}) and does not directly involve the DNA damage response to double-strand breaks induced by IR or HU ([Figure 5B and C](#fig5){ref-type="fig"}). Although Atmin has been implicated directly as a transcription factor for *Dynll1* ([@bib29]), a broader role for Atmin in transcriptional regulation had not yet been determined. We find here that *Atmin* loss leads to widespread rescue of glioma-associated changes in gene expression in the *p53^∆N^*background. Several of these genes could be collectively responsible for suppressing GBM formation in *Atmin^ΔN^*; *p53^∆N^* animals. The most compelling single candidate, however, is the proto-oncogene *Pdgfra*. It has been shown that stimulating Pdgf signaling in vivo is sufficient to induce glioma-like growths ([@bib25]). Moreover, *PDGFRA* is commonly overexpressed in human glioma ([@bib14]), but only a subset of gliomas display *PDGFRA* locus amplification ([@bib15]) ([@bib9]), indicating that additional mechanisms drive its increased expression. *PDGFRA* overexpression frequently correlates with LOH on chromosome 17p, where the human *TP53* gene is located ([@bib22]), supporting the view that the oncogenic misexpression of *PDGFRA* might be a direct consequence of TP53 inactivation in human GBM. In our murine and human glioma lines, Pdgfra levels could be dynamically modulated by depleting Atmin or inhibiting Atm. At present, how Atm/Atmin controls Pdgfra expression in this background is unclear. Chromatin immunoprecipitation experiments in murine NSCs indicated that Atmin does not bind the *Pdgfra* gene (unpublished observations), making the regulation unlikely to be via direct transactivation, most likely involving currently unidentified intermediate transcriptional regulators of *Pdgfra* expression. We speculate that Trp53 controls the expression of a negative regulator of Pdgfra, for example, a repressor or a miR RNA, and that Atm signalling is required for the expression or function of this factor. As these intermediate factors could be promising targets for pharmacological inhibition, further investigation into their identity is of therapeutic interest.

Although the oncogenic role of PDGFR signaling in glioma is well established, the clinical efficacy of PDGFR inhibitors has so far been disappointing ([@bib58]; [@bib44]). Here, we demonstrate that the effect of these drugs on the proliferation and survival of human glioma cells can be greatly potentiated by combining PDGFR inhibitor treatment with ATM inhibitors. Importantly, the strongest effects of combinatorial treatment on cell proliferation and survival are specific to tumor cells that have lost TP53 function, suggesting that systemic therapy should target TP53-deficient tumors with minimal impairment to normal tissue.

A second encouraging result of combining ATM and PDGFRA inhibitors is that they not only reduce tumor cell proliferation, but also potently induce cell death. While our data support cooperation based on simultaneous inhibition of PDGFR signaling at the transcriptional and protein kinase levels, it is likely that this synergy also encompasses broader effects of ATM and PDGFRA inhibition. In addition, current PDGFR inhibitors are not completely specific and also inhibit EGFR, VEGFR, FLT3, and c-KIT kinases amongst others ([@bib1]; [@bib24]). Similarly, ATM inhibitors have also been shown to display broader kinase inhibitor activity, especially at higher concentrations ([@bib23]). Thus, PDGFR-independent mechanisms could contribute to the observed treatment synergy.

In summary, we have identified a novel protumorigenic function of ATM signaling in GBM. Our results present a rationale for expanding the investigation of ATM inhibitors from radiosensitizers to potential therapies in their own right, and point toward improvements in the efficacy of PDGFRA inhibition using combination treatment.

Materials and methods {#s4}
=====================

Ethics statement {#s4-1}
----------------

Experiments in mice were carried out with the approval of the Crick Institute's Ethical Review Committee and under the guidance of the Biological Resources Unit.

Animal models {#s4-2}
-------------

*Atmin^f/f^*, *p53^f/f^, Atm*^-/-^, and *Nestin-Cre* mice have been described previously ([@bib31]; [@bib27]; [@bib3]; [@bib51]). Immunocompromised NOD/SCID mice were maintained in-house. Mice were maintained and bred on a mixed background in pathogen-free conditions, monitored for signs of ill health and culled when moribund. Strain background had no significant effect on the latency or development of gliomas in *p53^ΔN^*mice.

Cell culture {#s4-3}
------------

NSCs were isolated as spheres from fore and midbrains of mouse E13.5 embryos. Cells were initially cultured as spheres under self-renewal conditions, as previously described. Adherent NSC cultures were derived as previously described ([@bib41]; [@bib11]) with minor modifications ([@bib45]). Briefly, primary spheres were plated in Neurobasal Medium (Invitrogen, Grand Island, NY, USA) supplemented with 1% Penicillin/Streptomycin (Invitrogen), 1% L-glutamine (Invitrogen), 2% B27 supplement (Invitrogen), 1% N-2 supplement (Invitrogen), 20 ng/ml EGF (PeproTech), 20 ng/ml FGF-basic (PeproTech), and 1 μg/ml laminin (Sigma). All experiments were performed using undifferentiated adherent NSCs (see [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

Primary tumor cells were generated from brain tumor samples of symptomatic mice ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}). Tissue was subjected to mechanical and enzymatic dissociation, and single cells initially cultured to form spheres. Tumor spheres formed were then maintained as adherent tumor cell cultures in NSC media as described above.

Plasmids and reagents {#s4-4}
---------------------

pCMV6-myc-ATMIN was generated by cloning mouse *Atmin* into a pCMV6 backbone. Silencing and mismatch constructs for *Atmin* have been described previously ([@bib30]). The luciferase p53 response element (pGL3-550RE) was kindly provided by Karen Vousden. The ATM inhibitor Ku55993 (Merck) was used at 10 µM and replenished every 24 hr.

For DNA damage induction, NSCs of the indicated genotypes were either left untreated or subjected to 0.8 Gy irradiation or 2 mM hydroxyurea (HU) and harvested after 1 hr and 3 hr respectively for RNA extraction or protein lysates.

Transfection and luciferase assay {#s4-5}
---------------------------------

For transfection, NSCs and GNSCs were plated at subconfluence and transfected with Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen).

For luciferase assays, samples were transiently transfected with Firefly and Renilla luciferase reporters and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega), 36-hr post-transfection. Data are expressed as fold induction of luciferase activity after being normalized to expression of thymidine kinase-renilla luciferase (TK-renilla).

Western blots and immunoprecipitation {#s4-6}
-------------------------------------

For Western Blots (WB), NSCs were extracted in RIPA lysis buffer (NEB) supplemented with protease inhibitors (Sigma). For immunoprecipitation (IP) cells were lysed in IP buffer (20mM sodium phosphate buffer, 1 mM EDTA, 0.2% NP40, 150 mM NaCl supplemented with Na-orthovanadate, PMSF, NaF and protease inhibitor mixture \[Sigma\]). After sonication and centrifugation, supernatant was incubated overnight at 4°C with PDGFRA antibody, followed by 2-hr incubation with Dynabeads M-280 (Invitrogen), washed with IP buffer (0 mM NaCl, 150 mM NaCl and 1 M NaCl) and eluted in Laemmli sample buffer. All primary antibodies were used at 1:1000 dilution and secondary antibodies at 1:10000. The following antibodies were used: p53, Pdgfra, p-Pdgfra, p-Chk2, p-Akt, Akt (all Cell Signaling); Myc-9E10 (CRUK); Smc1 (Abcam); p-Smc1, Chk2, Tubulin (all Merck); p-Kap1, Kap1 (both Bethyl Labs); Atm (Santa Cruz), p-Atm (Epitomics), p-p53, Actin, GAPDH, HRP-conjugated goat anti-mouse/rabbit IgG (all Sigma).

Quantitative RT-PCR {#s4-7}
-------------------

For qRT-PCR analysis, mRNA was isolated from NSCs using the RNeasy mini kit (Qiagen). Results (normalized to *Actin* expression) are presented as fold change relative to control. Sequences of primers used are listed in [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}.

Cell proliferation and hypoxia assays {#s4-8}
-------------------------------------

For cell proliferation assays, NSCs were plated in duplicate in 12-well plates and cell number measured every day using a ViCell cell counter. The initial number of cells seeded was used to normalize to 100%. Mean averages were taken from at least four independent lines per genotype taken from different embryos and crosses. For BrdU profiling, cells pulsed with BrdU for 2 hr were fixed in 70% ethanol, stained with BrdU antibody and propidium iodide (PI) and analyzed by flow cytometry.

For hypoxia assay, NSCs were seeded in duplicate into 6-well plates and next day placed into a hypoxic chamber at 0.1% O~2~ for 72 hr. ATM inhibitor was replenished after 24 hr and 48 hr. For cell death analysis, control-treated and hypoxia-treated cells were subjected to DAPI staining and analyzed via flow cytometry. Mean averages were taken from at least three independent experiments.

IR-induced death and arrest {#s4-9}
---------------------------

To determine IR-induced death, NSCs were irradiated at 5Gy and after 24 hr incubated with 4\'-6-Diamidino-2-phenylindole (DAPI; Sigma) and assessed for apoptosis via flow cytometry. G1/S phase arrest was assessed by irradiating NSCs at 5Gy and after 18 hr pulsing with BrdU for 1.5 hr. Cells were prepared for flow cytometry as described above and gated on BrdU-positive cells. Mean averages were taken from at least three independent experiments.

Orthotopic transplants {#s4-10}
----------------------

1x10^5^ early passage (p.4) GFP labeled NSCs of the indicated genotypes were injected using a stereotaxic frame into the striatum of 6- to 8-week-old mice (NOD/SCID strain), following administration of general anaesthesia as previously described. Animals were monitored daily and culled when moribund.

Human NS and GNS cell culture {#s4-11}
-----------------------------

Fetal NS cell lines and GNS lines derived from human glioma samples have been described previously ([@bib48]; [@bib42]). The same culture conditions apply as previously described for mouse NSCs. Cell proliferation was measured over a period of four or seven days using an incubator microscope system for live cell imaging and measurement of cell confluence over several days (IncuCyte) and cell death was quantified using CellPlayer Caspase 3/7 Reagent from Essen Bioscience. Cells were seeded at 1.2x10^4^ or 2.4x10^4^ into a 48-well plate and images taken every 30 min. The ATM inhibitor KU55993 was added at 10 μM. PDGFR inhibitors III and V (CAS 205254-94-0 and CAS 347155-76-4 respectively, both Merck) were used at 1μM and replenished every 24 hr over a period of four or seven days as indicated. Stable sh*PDGFRA* GNSC lines were generated by viral infection of GNSCs with pTRIPZ-sh*PDGFRA* targeting and control vectors (Thermo Fisher). Doxycycline was added at a final concentration of 0.5 μg/ml and replenished every day.

Histological analysis and tumor grading {#s4-12}
---------------------------------------

All mice were euthanized in a CO~2~ chamber to preserve brain tissue. Brain sections were cut at 4 μm for Hematoxylin & Eosin (H&E) staining and all antibody staining. The following antibodies were used for IHC: Nestin (BD Bioscience), Gfap (Dako), Olig2, Neun (both Merck), Synaptophysin (Sigma), Pdgfra (Cell Signaling), Ki67 (Abcam). Tumor grading was determined on the basis of the WHO grading system for malignant astrocytoma.

Microarray analysis {#s4-13}
-------------------

Three independent NSC lines from each indicated genotype were pooled and submitted for genome wide gene expression profiling using the Illumina Mouse ref 8 v3.0 expression bead chip. Raw data were processed using the \'lumi\' package ([@bib13]) within Bioconductor ([@bib16]) first by applying the variance-stabilizing transform, and then carrying out quantile normalization. Following this, genes were selected on the basis of a 1.5-fold threshold on the mean of the technical duplicates (technical correlation being higher than 0.996 in all cases). The microarray data depicted in [Figure 3A](#fig3){ref-type="fig"} has been uploaded to the GEO database under the accession number GSE76296.

Using our normalised microarray data, we calculated the average log fold change between each condition and the wild-type samples. We then calculated distance (following the procedure of \[[@bib12]\]) of these expression profiles to the centroids of the four GBM subtypes identified in ([@bib54]). We mapped the expression profile from mouse to human by matching up gene names between the two species, resulting in a correspondence for 674 of the 840 genes in the GBM signature. To assess informally the specificity of the subtypes, and to gain some insight into the strength of the similarities to GBM subtypes, we bootstrapped the log fold changes within samples 1000 times, recording the pairwise distances between bootstrapped samples and fixed GBM subtype-centroids.

Copy number variation calling {#s4-14}
-----------------------------

Total genomic DNA was extracted and purified using DNeasy Blood & Tissue Kit (Qiagen). Copy number variation (CNV) detection was performed using the Affymetrix Mouse Diversity Genotyping Array (MDGA) at AROS Applied Biotechnology. Genotypes were called from the CEL files using the BRLMM-P algorithm in Affymetrix Power Tools (APT) (available from: <http://www.affymetrix.com/estore/partners_programs/programs/developer/tools/powertools.affx>) using default settings, including quantile normalization. PennAffy (available from: <http://penncnv.openbioinformatics.org/en/latest/user-guide/download/>) was implemented to generate Log R Ratio (LRR) and B-allele frequency (BAF) using canonical genotype clustering and population frequency of the B-allele (PFB) files kindly provided by Locke et al. ([@bib34]). Markers that do not probe allelic balance (exon markers in the MDGA) were removed. GC content was calculated for 1 Mb windows centred by each marker using BEDTools ([@bib43]). LRR was then corrected for genomic waviness by subtracting the median normalised GC content multiplied by a coefficient optimised to generate the minimum variance when subtracted from the LRR. Copy number states were then called for mouse autosomes using the 'CGHcall' R package ([@bib52]) in Bioconductor ([@bib16]) using the \'sdundo\' option for the undo.splits parameter for segmentation. Only CNVs larger than 1 Mb were reported.

TCGA data analysis {#s4-15}
------------------

Gene expression measurements were obtained by downloading the \'Glioblastoma Multiforme (TCGA, provisional)\' dataset using the cBioPortal (<http://www.cbioportal.org/>, version 05/09/2014) for The Cancer Genome Atlas (<http://cancergenome.nih.gov/>). The dataset contained 500 microarrays and 153 RNA-seq measurements for 518 glioblastoma patients. Glioblastoma expression subgroup information was obtained from ([@bib8]), and gene expression levels were represented as z-scores. The RNA-seq and microarray data were analyzed separately but the z-scores for *PDGFRA* are correlated across 135 samples for which both data types are available (Spearman correlation coefficient = 0.85 for 135 samples with both RNA-seq and microarray data, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), indicating that the two measurement types are comparable. Differences in expression z-scores between *TP53* mutant and *TP53* wt status, as well as glioblastoma subgroups (combining GCiMP and Proneural versus Neural, Classical, and Mesenchymal) were tested using the Wilcoxon's test. Three outlier points from each of the TP53 wt and mutant groups in [Figure 6D](#fig6){ref-type="fig"}, as well as six outlier points (5 Proneural and 1 Mesenchymal) in [Figure 6E](#fig6){ref-type="fig"} are excluded from the plot for clarity.

Statistical analysis {#s4-16}
--------------------

Tumor-free survival was analyzed using GraphPad Prism 6 and statistical analyses to determine tumor-free survival were performed using the Mantel-Cox test. For TCGA data analysis p values were determined using the Wilcoxon's test. For all other experiments with error bars, the unpaired Student's t-test was performed to determine statistical significance.
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The following datasets were generated:

Behrens A, Blake S,2015,ATMIN function in p53-deficient GBM,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76296>,Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE76296)

The following previously published dataset was used:

Glioblastoma Multiforme,2014,Glioblastoma Multiforme (TCGA, provisional),<http://cancergenome.nih.gov/>,Publically available
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Decision letter

Gilbertson

Richard J

Reviewing editor

Cambridge Cancer Center, CRUK Cambridge Institute

,

United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation\" for peer review at *eLife*. Your submission has been favorably evaluated by Sean Morrison (Senior editor), a Reviewing editor, and three reviewers.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

This manuscript describes an interesting pro-tumorigenic role for ATMIN mediated ATM signaling in glioblastoma. Specifically, the authors demonstrate that the concomitant loss of ATMIN and p53 in nestin positive cells in mice, reduces glioma formation. This result is recapitulated in a transplant model using neural stem cells. The authors conclude that p53 drives glioma, and that the resulting tumors activate PDGFRa through an ATM and ATMIN dependent pathway.

In order for us to consider your manuscript further, please pay close attention to the following critiques.

Essential revisions:

1\) Comment on the potential importance of ROS in the transforming mechanism described in the paper.

2\) The authors should provide the complete microarray data in an appropriate format.

3\) Demonstrate that ATMi and *Pdgfra* were was within a reasonable dose range, clarify dose and dose response against ATM and PDGFRa phosphorylated substrates, to assure that effects seen were on rather than off-target.

4\) Explain why, if ATMIN sub serves ATM downstream signaling as its primary output, deletion of ATMIN ([Figure 2G](#fig2){ref-type="fig"}) was more effective than deletion of ATM ([Figure 4H](#fig4){ref-type="fig"}) in reducing tumorgenicity.

5\) Discuss how ATM and ATMIN contribute to elevated *Pdgfra* signaling in this model.

6\) The conclusion that alterations observed in experimental gliomas are real tumors with secondary genetic changes requires characterizing the genetic status of the tumors by SNP or CGH arrays.

*Reviewer \#1:*

This manuscript describes an unexpected pro-tumorigenic role for ATMIN mediated ATM signaling in glioblastoma using a variety of mouse and human models. The deletion of both ATM and ATMIN in mice, and in the case of ATM, humans, leads to the development of different types of tumors, primarily of lymphocyte origin. Thus both ATM and ATMIN are primarily regarded as tumor suppressors. Recent work has established that ATM may have some pro-tumorigenic roles through its functions in differentiation and secretory phenotypes in different tumor models (Santos et al., Nature 2014 and Chen et al., *ELife* 2015).

The authors demonstrate that the concomitant loss of ATMIN in mice where p53 has been deleted by Nestin-Cre reduces tumor formation that is primarily of glioblastoma origin. This result is convincingly recapitulated in a transplant model using NSCs. The authors identified PDGFRa as a gene strongly affected by ATMIN or ATM status in the p53∆ tumors and demonstrated that its levels affected cell growth through a variety of complementary experiments. Finally, the authors demonstrate that combined inhibition of both ATM and PDGFR increases cell death and decreases proliferation in human glioblastoma cell lines with elevated PDGFRa and mutant p53.

The work is generally of high quality and will be of interest to numerous fields for the following reasons: 1) This adds to a growing body of evidence that ATM signaling can have both pro and anti-tumorigenic roles, and thus provide information regarding the appropriate use of ATM inhibitors; 2) It establishes in some further detail that p53-Nestin-Cre deletion is a useful glioblastoma model, a point that I think is not widely appreciated; 3) It identifies PDGFRa as a downstream player in ATM/ATMIN signaling that may also be relevant in other contexts; and 4) It establishes some proof of principal that ATM inhibitors may be useful to combine with PDGFRa depletion in p53 mutant glioblastomas. While there are some mechanistic details that are not well established, primarily the mechanism by which ATM upregulates PDGFRa and the trigger for ATMIN/ATM activation in the p53 null tumors, the establishment of all of these details would likely not have a strong impact on the primary conclusions of the paper.

Comments:

1\) In the last paragraph of the subsection "*Pdgfra* overexpression is reversible with pharmacological ATM inhibition", the authors conclude that \"*Pdgfra* upregulation is not a consequence of stimulation of DNA damage signaling\" based on the observation that HU or IR do not upregulate *Pdgfra* levels, and the lack of differences in some ATM substrates. Previous work from this group and others (Kanu and Behrens, EMBO J. 2007 and Jurado et al. 2010) has made the point that ATMIN does not seem to play a prominent role in the activation of ATM in response to IR or HU but is a major player in the response to reactive oxygen. The inhibitor experiments argue that ATM activity is required and it is thus presumably activated in the presence of ATMIN. Given that ROS is linked to the activation of ATM by ATMIN, p53 signaling (Liu et al., Free Radical Biol Med (review) 2008) and implicated in PDGFRa activity (Lei and Kazlauskas, MCB 2013), it seems that this would be an important stimuli to test before making this very definitively stated conclusion.

2\) The authors should provide the complete microarray data, as there are a number of other genes altered by ATMIN depletion that may be of interest for understanding the phenotypes (possibly factors induced by ROS for example?) and potential impact on therapy.

*Reviewer \#1 (Additional data files and statistical comments):*

As indicated in the previous comments, the microarray data should be supplied (and deposited to the appropriate public database) and additional data regarding the numbers of technical or biological replicates used in any of the statistical analyses should be clearly stated.

*Reviewer \#2:*

This is an interesting if somewhat preliminary manuscript that argues, based initially on in vivo mouse modeling, that loss of p53 drives glioma, and that the resulting tumors activate PDGFRa through an ATM and ATMIN dependent pathway. While this pathway is new, no mechanism is revealed for how p53 signals through ATM to drive PDGFRA. In addition, the authors argue based solely on cell line data, for enhanced effects when combining PDGFR and ATM inhibitors for preclinical therapies.

1\) Can the authors subclassify mouse and human p53 mutant GBM based on TCGA classification? *Pdgfra* is enriched in proneural GBM. It would be important to know whether p53 mt murine GBM are proneural. This is also relevant for [Figure 6](#fig6){ref-type="fig"}. What is TCGA classification of GNSCs used, are these also proneural? If not, do the authors think that this mechanism is relevant for all subtypes?

The authors should show that ATMi and *Pdgfra* used was within a reasonable dose range, clarify dose and dose response against ATM and PDGFRa phosphorylated substrates, to assure that effects seen were on rather than off-target.

If ATMIN sub serves ATM downstream signaling as its primary output, why was deletion of ATMIN ([Figure 2G](#fig2){ref-type="fig"}) more effective than deletion of ATM ([Figure 4H](#fig4){ref-type="fig"}) in reducing tumorgenicity.

The authors show that induction of *Pdgfra* in p53mt NSCs is not a consequence of DNA damage signaling. So how do ATM and ATMIN contribute to elevated *Pdgfra* signaling in this model?

The result of PDGFRA depletion is only shown in a single human cell line.

As the authors mention, PDGFRi has, so far, failed transition to clinical practice. Is the effect, and particularly the apoptosis observed in vitro here, translatable to an in vivo setting? The authors argue that combined inhibition of ATM and PDGFR promises new opportunities for future GBM treatment. The addition of in vivo experiments is critical here to substantiate this statement, and to determine whether this effect really drives apoptosis, and with it, regression of established tumors.

Reviewer \#2 (Additional data files and statistical comments):

No issues for me, except to wonder about differences between loss of ATMIN and loss of ATM, listed above.

*Reviewer \#3:*

The paper \"Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation\" reports studies in a *Nestin-Cre (p53^ΔΝ^)* model in which the activation of the gene ATMIN is identified as an important event downstream to p53 deletion to implement the tumorigenic phenotype in the brain. Mechanistically, the authors suggest that ATMIN is required to sustain the high expression of PDGFRA in this model.

The development of a new, albeit predictable model of brain tumors obtained by deleting p53 in the neural stem cell compartment is a potentially interesting finding. However, the role played by ATMIN in the tumorigenic process and especially the suggestion that ATMIN is a factor required for the overexpression of PDGFRA remain of uncertain significance. Conversely, it seems that the findings reported are limited to the mouse model under investigation and unlikely to have an impact for the biology of human glioma. Indeed, the main weakness of the manuscript is that in human glioma the high expression of PDGFRA (in the presence or absence of p53 mutations) occurs through gene amplification and it is therefore unlikely that ATMIN plays any role for PDGFRA overexpression. Furthermore, there are no known genetic alterations reported to target ATMIN in human malignant glioma.

Therefore, while the phenotypic alterations characterized by the authors have relevance in the mouse model under investigation, there is no indication that the information contained in this manuscript has any relevance for the human disease.

Specific points:

1\) Although the authors perform a phenotypic characterization of the brain lesions occurring in the *Nestin-Cre (p53^ΔΝ^)* mouse, the conclusion that the alterations they observe are real tumors with secondary genetic changes requires characterizing the genetic status of the tumors by SNP or CGH arrays.

2\) PDGFRA is amplified and overexpressed in the subgroup of human GBM defined as proneural. Do the *Nestin-Cre (p53^ΔΝ^)* tumors belong to this molecular subgroup?

3\) The authors state that p53 alterations are early events, implicated in GBM initiation. It is not clear where the authors obtain this information, especially in the context of the human disease.

4\) In [Figure 2](#fig2){ref-type="fig"}, hypoxia has only a minor ability to induce apoptosis if compared with the effects produced by IR. Therefore, the rescue of this effect by loss of ATMIN is similarly of limited significance.

5\) The authors show that the integrity of the ATMIN gene is essential to preserve overexpression of PDGFRA in the *Nestin-Cre (p53^ΔΝ^)* mouse model. However, this leaves open the question of whether PDGFRA overexpression is sufficient to reverse the effects of ATMIN deletion. The authors should address this question through reconstitution of the expression of PDGFRA in *Nestin-Cre (p53^ΔΝ^) Atmin^ΔΝ^* mouse.

10.7554/eLife.08711.043

Author response

Essential revisions:

*1) Comment on the potential importance of ROS in the transforming mechanism described in the paper.*

ROS is an important regulator of ATM signalling. ATM can be activated by ROS by the introduction of a disulfide bond (Guo et al. Science 330, 517-521, 2010), and under certain oxidising conditions ATM function requires ATMIN (Kanu et al. J Biol Chem 285, 38534--38542, 2010). Moreover, ROS levels are increased in ATM mutant cells, and strikingly, thymomas in ATM mutant mice can be significantly delayed by anti-oxidants treatment (Reliene et al. 2007).

Importantly, constitutive "baseline" ATM/ATMIN signaling is required for *pdgfr* regulation, and what we view as "baseline" could actually represent ATM signalling induced by endogenous ROS. We have now amended the Results section to specify that the DNA damage signalling we refer to at that point is that induced by IR and HU, not ROS.

Results section:

"This suggests that while ATM is required for the increased *Pdgfra* expression in *p53^ΔN^* cells, this does not involve alterations in IR or HU-induced ATM signaling, but at this point does not exclude the possibility that increased ROS (reactive oxygen species) levels in p53^∆N^ GBM cells might contribute to ATM pathway activation and subsequent *Pdgfra* induction and GBM development."

*2) The authors should provide the complete microarray data in an appropriate format.*

The microarray data depicted in [Figure 3A](#fig3){ref-type="fig"} has been uploaded to the GEO database under the accession number GSE76296 and made publically available (the data can be viewed at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76296>). This information is now also mentioned in the corresponding Materials and methods section.

**"**Microarray analysis:

Three independent NSC lines from each indicated genotype were pooled and submitted for genome wide gene expression profiling using the Illumina Mouse ref 8v3 expression bead chip. \[...\] The microarray data depicted in [Figure 3A](#fig3){ref-type="fig"} has been uploaded to the GEO database under the accession number GSE76296."

*3) Demonstrate that ATMi and Pdgfra were was within a reasonable dose range, clarify dose and dose response against ATM and PDGFRa phosphorylated substrates, to assure that effects seen were on rather than off-target.*

We have performed dose titration experiments in GNSCs for both the ATM and PDGFRa inhibitors and can confirm that the concentrations chosen for the experiments were the minimally required concentrations to achieve target and downstream pathway inhibition([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}).

ATM: We used 10µM of ATMi in our experiments. GNSCs were treated with DMSO or 400nM, 2µM or 10µM of ATMi for 16 hrs, then subjected to 5Gy of ionizing irradiation and harvested 30 minutes later. Pre-treatment of cells with the ATMi at 10µM clearly prevented auto-phosphorylation of ATM at Serine residue 1981, indicative of ATM activation, and the phosphorylation of the well-characterized ATM substrates Kap1 and Chk2, whereas the lower tested doses were not able to fully inhibit substrate phosphorylation. This shows that the applied concentration of the inhibitor in the performed experiments efficiently inhibited ATM activity.

For PDGFRa inhibition, we used 1µM of inhibitor in our experiments. To test PDGFRa activity, GNSCs were treated with DMSO, 200nM or 1µM of PDGFRa inhibitor for 2hrs. PDGFRa activation was measured by IP of PDGFRa, followed by western blot for phosphorylated *Pdgfra* tyrosine residue 754, a hallmark of *Pdgfra* activation. 1µM inhibitor clearly reduced phosphorylation of *Pdgfra* at Tyrosine residue 754 and also reduced the phosphorylation of the downstream substrate Akt at Serine residue 473. Hence, 1µM, but not 200nM PDGFRa inhibitor, blocks substrate and downstream target phosphorylation/signaling.

*4) Explain why, if ATMIN sub serves ATM downstream signaling as its primary output, deletion of ATMIN ([Figure 2G](#fig2){ref-type="fig"}) was more effective than deletion of ATM ([Figure 4H](#fig4){ref-type="fig"}) in reducing tumorgenicity.*

Although the primary output of ATMIN signaling is mediated by the upstream kinase ATM, it is also clear that ATMIN has additional, ATM independent, functions. ATMIN has been shown to bind chromatin and act as transcriptional regulator in several cell types (Goggolidou et al., 2014; Jurado et al., 2012; Jurado et al., 2011). Therefore, in addition to sub-serving ATM, ATMIN also has ATM independent functions. A single one, or more likely, a combination of these ATMIN target genes may be responsible for the enhanced anti-tumorigenic effect observed.

We now discuss this in the Results section:

"However, ATMIN deletion ([Figure 2G](#fig2){ref-type="fig"}) was more effective than deletion of ATM ([Figure 4H](#fig4){ref-type="fig"}). ATMIN can also act as a transcription factor (Jurado et al., 2012; Goggolidou et al., 2014; Jurado et al., 2012), and it is conceivable that this ATM-independent function of ATMIN contributes to the suppression on GBM."

*5) Discuss how ATM and ATMIN contribute to elevated Pdgfra signaling in this model.*

Analysis of published ENCODE data sets failed to reveal binding of p53 to the *PDGFR* promoter. Similarly, our in house ChIP-Seq experiments showed no ATMIN occupancy on the *PDGFR* promoter; Kanu et al., unpublished). Therefore the antagonistic regulation of *PRGFR* expression by p53 and ATM/ATMIN signalling must be indirect.

We speculate that p53 controls the expression of a negative regulator of *PDGFR*, e.g. a repressor or a miR RNA, and that ATM signalling is required for the expression or function of this factor. We have discussed this in the revised manuscript.

As the microarray data reveals 39 up-regulated and 41 repressed genes specifically altered in the double mutant cells vs. the p53 single mutants, it will require a designated pooled shRNA/CRISPR screen to confirm or de-validate this hypothesis. We aim to perform these experiments in follow up projects.

Discussion section:

"In our murine and human glioma lines *Pdgfra* levels could be dynamically modulated by depleting ATMIN or inhibiting ATM. \[...\] As these intermediate factors could be promising targets for pharmacological inhibition, further investigation into their identity is of therapeutic interest."

*6) The conclusion that alterations observed in experimental gliomas are real tumors with secondary genetic changes requires characterizing the genetic status of the tumors by SNP or CGH arrays.*

This is an excellent comment from the reviewer and we have addressed this question by conducting SNP array analysis for primary cells derived from 5 *p53^ΔN^* gliomas. One adult *wt* NSCs as well as 3 non-tumorigenic adult *p53^ΔN^* NSCs were used as controls. The results from the SNP array are depicted in ([Figure 1---figure supplements 3](#fig1s3){ref-type="fig"} and [4](#fig1s4){ref-type="fig"}) and referenced in the Results section of the manuscript. The SNP array analysis was performed on Affymetrix® Mouse Diversity Genotyping arrays and showed, that no whole chromosome copy number variations or copy number variations larger than the defined detection limit (\> 1 Mb) were found in *wt* NSCs or p5*3^ΔN^*NSCs, confirming that these cells have not developed secondary alterations. In contrast, large chromosomal gains and losses (typical tumorigenic genetic changes) were found in 4 out of 5 analysed *p53^ΔN^*glioma cell lines, confirming the presence of secondary genetic alterations in these cell lines, while not excluding the further presence of point mutations, insertions/deletions that are smaller than 1 Mb.

Results section:

"The long latency of these tumors, together with the genome instability and transcriptional changes known to be induced by loss of p53, indicated that these gliomas almost certainly develop as a result of secondary mutations arising in the p53-null brain. In line with this notion, SNP array revealed large chromosomal gains and losses (typical tumorigenic genetic changes) in 4 out of 5 analysed *p53^ΔN^* gliomas whereas no changes were detected in 1 wt and 3 p53-deficient non-tumorigenic control NS cells."

Reviewer \#1: Comments:

*1) In the last paragraph of the subsection "Pdgfra overexpression is reversible with pharmacological ATM inhibition", the authors conclude that \"Pdgfra upregulation is not a consequence of stimulation of DNA damage signaling\" based on the observation that HU or IR do not upregulate Pdgfra levels and the lack of differences in some ATM substrates. Previous work from this group and others (Kanu and Behrens, EMBO J. 2007 and Jurado et al. 2010) has made the point that ATMIN does not seem to play a prominent role in the activation of ATM in response to IR or HU but is a major player in the response to reactive oxygen. The inhibitor experiments argue that ATM activity is required and it is thus presumably activated in the presence of ATMIN. Given that ROS is linked to the activation of ATM by ATMIN, p53 signaling (Liu et al., Free Radical Biol Med (review) 2008) and implicated in PDGFRa activity (Lei and Kazlauskas, MCB 2013), it seems that this would be an important stimuli to test before making this very definitively stated conclusion.*

We thank the referee for this important comment. And have addressed this comment in our reply to the Editorial comment 1.

*2) The authors should provide the complete microarray data as there are a number of other genes altered by ATMIN depletion that may be of interest for understanding the phenotypes (possibly factors induced by ROS for example?) and potential impact on therapy.*

We now provide the complete microarray data, as described in our response to the Editorial comment 2.

*Reviewer \#1 (Additional data files and statistical comments): As indicated in the previous comments, the microarray data should be supplied (and deposited to the appropriate public database) and additional data regarding the numbers of technical or biological replicates used in any of the statistical analyses should be clearly stated.*

In response to this reviewer's comment and the Editorial comment 2, we have deposited the microarray data in the GEO database with the accession number GSE76296. In addition, the data regarding the numbers of technical or biological replicates used for the statistical analyses are now included in the figure legends of the revised manuscript.

*Reviewer \#2: This is an interesting if somewhat preliminary manuscript that argues, based initially on in vivo mouse modeling, that loss of p53 drives glioma, and that the resulting tumors activate PDGFRa through an ATM and ATMIN dependent pathway. While this pathway is new, no mechanism is revealed for how p53 signals through ATM to drive PDGFRA. In addition, the authors argue based solely on cell line data, for enhanced effects when combining PDGFR and ATM inhibitors for preclinical therapies. 1) Can the authors subclassify mouse and human p53 mutant GBM based on TCGA classification? Pdgfra is enriched in proneural GBM. It would be important to know whether p53 mt murine GBM are proneural. This is also relevant for [Figure 6](#fig6){ref-type="fig"}. What is TCGA classification of GNSCs used, are these also proneural? If not, do the authors think that this mechanism is relevant for all subtypes?*

To address this valid point, we compared our data to the TCGA classification of human GBM as described in (Verhaak et al., 2010).This analysis revealed that the only transcriptional profile that significantly resembles any of the human TCGA defined subtypes, is the one derived from *p53^ΔN^*NSCs. These cells show close relation to the human pro-neural subtype. We now report this observation in the Results section of the manuscript and have added the corresponding data analysis as a new supplementary figure ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

Results section:

**"**Increased PDGFRa levels are also a characteristic hallmark of the proneural GBM subtype as classified in (Brennan et al., 2013; Verhaak et al., 2010). Interestingly we found that *p53^ΔN^* NSCs were associated most closely with the proneural subtype when comparing the microarray expression profile from the murine NSCs to that of publically available human GBM samples from TCGA (Verhaak et al., 2010) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), which is in agreement with elevated *Pdgfra* mRNA as well as protein levels ([Figure 3D](#fig3){ref-type="fig"})."

*The authors should show that ATMi and Pdgfra used was within a reasonable dose range, clarify dose and dose response against ATM and PDGFRa phosphorylated substrates, to assure that effects seen were on rather than off-target.*

We have addressed this important suggestion and shown that the chosen dose was required and sufficient to engage the target and display downstream pathway modulation. Please see our response to the Editor's comments 3 and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}.

*If ATMIN sub serves ATM downstream signaling as its primary output, why was deletion of ATMIN ([Figure 2G](#fig2){ref-type="fig"}) more effective than deletion of ATM ([Figure 4H](#fig4){ref-type="fig"}) in reducing tumorgenicity.*

ATMIN has a dual function, as an ATM cofactor and as a transcription factor. As discussed in more detail in the response to Editor's comments 4, we speculate that the function of ATMIN as transcription factor contributes to the pro-tumorigenic effect observed.

*The authors show that induction of Pdgfra in p53mt NSCs is not a consequence of DNA damage signaling. So how do ATM and ATMIN contribute to elevated Pdgfra signaling in this model?*

It is interesting to speculate how p53 and ATMIN/ATM signalling control PDGFRa expression, which has been addressed in more detail in the Editor's comment 5. In brief, the regulation is most likely indirect, and possibly involves a p53-regulated factor that requires ATM activity for function.

The result of PDGFRA depletion is only shown in a single human cell line.

We agree with the reviewer's comment about the limited sample number in the PDGFRa knockdown experiments. We generated this Dox-inducible p53-deficent cell line allowing PDGFR depletion to provide a proof of principle validation for PDGFRa function. We have followed this in using 2 different PDGFRa inhibitors, in 3 independent (one wild-type and 2 p53-deficient) human derived neural stem cell lines. As shown in [Figure 7](#fig7){ref-type="fig"} and [Figure 7---figure supplements 2](#fig7s2){ref-type="fig"} and [3](#fig7s3){ref-type="fig"} both inhibitors display similar effects. We hope that this is satisfactory to demonstrate the involvement of PDGFRa function in glioma stem cell function.

As the authors mention, PDGFRi has, so far, failed transition to clinical practice. Is the effect, and particularly the apoptosis observed in vitro here, translatable to an in vivo setting? The authors argue that combined inhibition of ATM and PDGFR promises new opportunities for future GBM treatment. The addition of in vivo experiments is critical here to substantiate this statement, and to determine whether this effect really drives apoptosis, and with it, regression of established tumors.

As the reviewer suggests, the combination therapy of ATM and PDGFR inhibitors in a pre-clinical setting is a logical next step. However, this experiment is extremely difficult to perform for two reasons. Firstly, the long latency of gliomas to arise in the p53 F/F; Nestin-Cre strain (around 300 days, [Figure 1A](#fig1){ref-type="fig"}), does not allow us to perform this experiment within the provided time of a normal revision process. Secondly, the ATM inhibitor has been shown to not cross the blood brain barrier (Biddlestone-Thorpe et al., 2013), essentially precluding the usage of the current generation of ATM inhibitors for this experiment, making it currently impossible to address this valid suggestion.

*Reviewer \#2 (Additional data files and statistical comments): No issues for me, except to wonder about differences between loss of ATMIN and loss of ATM, listed above.*

As described in more detail in our response to the Editor's comment 4, we speculate that this is due to a pro-tumorigenic role of ATMIN-mediated transcription.

*Reviewer \#3: The paper \"Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation\" reports studies in a Nestin-Cre (p53^ΔΝ^) model in which the activation of the gene ATMIN is identified as an important event downstream to p53 deletion to implement the tumorigenic phenotype in the brain. Mechanistically, the authors suggest that ATMIN is required to sustain the high expression of PDGFRA in this model.*

*The development of a new, albeit predictable model of brain tumors obtained by deleting p53 in the neural stem cell compartment is a potentially interesting finding. However, the role played by ATMIN in the tumorigenic process and especially the suggestion that ATMIN is a factor required for the overexpression of PDGFRA remain of uncertain significance. Conversely, it seems that the findings reported are limited to the mouse model under investigation and unlikely to have an impact for the biology of human glioma. Indeed, the main weakness of the manuscript is that in human glioma the high expression of PDGFRA (in the presence or absence of p53 mutations) occurs through gene amplification and it is therefore unlikely that ATMIN plays any role for PDGFRA overexpression. Furthermore, there are no known genetic alterations reported to target ATMIN in human malignant glioma.*

*Therefore, while the phenotypic alterations characterized by the authors have relevance in the mouse model under investigation, there is no indication that the information contained in this manuscript has any relevance for the human disease. Specific points:*

*1) Although the authors perform a phenotypic characterization of the brain lesions occurring in the Nestin-Cre (p53^ΔΝ^) mouse, the conclusion that the alterations they observe are real tumors with secondary genetic changes requires characterizing the genetic status of the tumors by SNP or CGH arrays.*

This is a very valid point and has been addressed in detail in our response to the Editor's comment 6. The corresponding data is presented in [Figure 1---figure supplement 3](#fig3){ref-type="fig"} and reported in the Results section of the manuscript.

Results section:

"The long latency of these tumors, together with the genome instability and transcriptional changes known to be induced by loss of p53, indicated that these gliomas almost certainly develop as a result of secondary mutations arising in the p53-null brain. In line with this notion, SNP array revealed large chromosomal gains and losses (typical tumorigenic genetic changes) in 4 out of 5 analysed *p53^ΔN^*gliomas whereas no changes were detected in 1 wt and 3 p53-deficient non-tumorigenic control NS cells."

*2) PDGFRA is amplified and overexpressed in the subgroup of human GBM defined as proneural. Do the Nestin-Cre (p53^ΔΝ^) tumors belong to this molecular subgroup?*

As mentioned in our response to the first comment of referee 2, we compared our data to the TCGA classification of human GBM as described in (Verhaak et al., 2010).This analysis revealed that the only transcriptional profile that significantly resembles any of the human TCGA defined subtypes, is the one derived from *p53^ΔN^*NSCs, and these cells show close relation to the human pro-neural subtype. We now report this observation in the Results section of the manuscript and have added the corresponding data analysis as a new supplementary figure ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

Results section:

**"**Increased PDGFRa levels are also a characteristic hallmark of the proneural GBM subtype as classified in (Brennan et al., 2013; Verhaak et al., 2010). Interestingly we found that *p53^ΔN^* NSCs were associated most closesly with the proneural subtype when comparing the microarray expression profile from the murine NSCs to that of publically available human GBM samples from TCGA (Verhaak et al., 2010) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), which is in agreement with elevated *Pdgfra* mRNA as well as protein levels ([Figure 3D](#fig3){ref-type="fig"})."

*3) The authors state that p53 alterations are early events, implicated in GBM initiation. It is not clear where the authors obtain this information, especially in the context of the human disease.*

We are sorry for not pointing this out more clearly. The articles cited in the main manuscript (Maher et al., 2001; Wang et al., 2009; Ohgaki et al., 2004), provide evidence to studies conducted in human patients as well as mouse models, showing that loss of p53 function is observable in both primary and secondary GBMs, concluding p53 loss to be an early event during gliomagenesis. We have now added an additional 2 references to the manuscript to further substantiate this claim.

*4) In [Figure 2](#fig2){ref-type="fig"}, hypoxia has only a minor ability to induce apoptosis if compared with the effects produced by IR. Therefore, the rescue of this effect by loss of ATMIN is similarly of limited significance.*

Compared to the IR induced cell death the effect of hypoxia on cell survival is indeed less pronounced. We would however like to stress that hypoxia is a hallmark of GBM tumours (e.g. Evans et al., 2004) what in our view warrants the inclusion of these data in the manuscript.

*5) The authors show that the integrity of the ATMIN gene is essential to preserve overexpression of PDGFRA in the Nestin-Cre (p53^ΔΝ^) mouse model. However, this leaves open the question of whether PDGFRA overexpression is sufficient to reverse the effects of ATMIN deletion. The authors should address this question through reconstitution of the expression of PDGFRA in Nestin-Cre (p53^ΔΝ^) Atmin^ΔΝ^ mouse.*

We agree with the reviewer that this indeed would be a very interesting point to address. However, as the tumor latency period of *p53^ΔN^* animals is approximately 1 year, and the cross of transgenic PDGFRa mice to the triple transgenic genotype would also require approx. 1 year, this experiment is unfortunately not within the scope of the study.
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